Valneva SE/€VLA
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Valneva SE
Valneva SE is a biotechnology company specializing in the development and commercialization of vaccines for infectious diseases. The company's portfolio includes vaccines for diseases such as Japanese encephalitis and cholera. Valneva is actively engaged in developing vaccines for Lyme disease and chikungunya. Founded in 2013 through the merger of Intercell AG and Vivalis, Valneva is headquartered in Saint-Herblain, France. The company operates primarily in Europe but has a global reach through various strategic partnerships and licensing agreements. Valneva's competitive strength lies in its focus on addressing unmet medical needs with its diverse pipeline of innovative vaccine candidates.
Ticker
€VLA
Sector
Primary listing
PAR
Employees
700
Headquarters
Website
Valneva SE Metrics
BasicAdvanced
€698M
-
-€0.42
1.01
-
Price and volume
Market cap
€698M
Beta
1.01
52-week high
€5.36
52-week low
€1.73
Average daily volume
183K
Financial strength
Current ratio
2.266
Quick ratio
1.476
Long term debt to equity
79.522
Total debt to equity
105.628
Interest coverage (TTM)
-2.10%
Profitability
EBITDA (TTM)
-33.421
Gross margin (TTM)
9.86%
Net profit margin (TTM)
-34.15%
Operating margin (TTM)
-25.18%
Effective tax rate (TTM)
-3.35%
Revenue per employee (TTM)
€280,000
Management effectiveness
Return on assets (TTM)
-6.58%
Return on equity (TTM)
-38.01%
Valuation
Price to revenue (TTM)
3.285
Price to book
3.63
Price to tangible book (TTM)
4.16
Price to free cash flow (TTM)
-23.988
Free cash flow yield (TTM)
-4.17%
Free cash flow per share (TTM)
-0.17
Growth
Revenue change (TTM)
25.47%
Earnings per share change (TTM)
78.90%
3-year revenue growth (CAGR)
-13.60%
10-year revenue growth (CAGR)
11.66%
3-year earnings per share growth (CAGR)
-34.59%
10-year earnings per share growth (CAGR)
7.65%
Bulls say / Bears say
The EMA lifted its temporary restriction on Ixchiq for adults aged 65 and over after a comprehensive safety review, enabling resumed use in elderly populations at significant risk of chikungunya (Reuters)
Ixchiq generated €7.5 million in the first half of 2025, representing over 8% of Valneva’s total product sales, and brokerage Kempen noted the share sell-off as an attractive buying opportunity (Reuters)
In June 2025, Valneva secured a three-year exclusive marketing and distribution agreement with CSL Seqirus for Germany, covering its chikungunya, Japanese encephalitis, and cholera vaccines with minimum annual purchase commitments to bolster European market penetration (Nasdaq)
The U.S. FDA suspended the license for Valneva’s chikungunya vaccine Ixchiq following four serious adverse event reports, forcing an immediate halt to U.S. distribution and sales (Reuters)
Valneva’s shares plunged about 25% on August 25, 2025 after the FDA suspension announcement, underscoring market concerns over a potential permanent withdrawal from the U.S. market (Reuters)
The EMA’s revised product information restricts Ixchiq use in immunocompromised patients and requires thorough benefit-risk assessment, narrowing the eligible patient population and limiting market size (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Valneva SE stock?
Valneva SE (VLA) has a market cap of €698M as of October 25, 2025.
What is the P/E ratio for Valneva SE stock?
The price to earnings (P/E) ratio for Valneva SE (VLA) stock is 0 as of October 25, 2025.
Does Valneva SE stock pay dividends?
No, Valneva SE (VLA) stock does not pay dividends to its shareholders as of October 25, 2025.
When is the next Valneva SE dividend payment date?
Valneva SE (VLA) stock does not pay dividends to its shareholders.
What is the beta indicator for Valneva SE?
Valneva SE (VLA) has a beta rating of 1.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.